A Study of Navenibart in Participants With Hereditary Angioedema
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent parti...
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angio...
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concen...
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared t...
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared ...
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II....
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-...
A Phase 2 in Adult Subjects With Hereditary Angioedema
A Phase 2 in Adult Subjects with Hereditary Angioedema...
Top Cities for Hereditary Angioedema Clinical Trials
Hereditary Angioedema clinical trials are recruiting across 47 cities. Here are the cities with the most active studies:
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic condition causing recurrent episodes of severe swelling in various body parts. It is caused by deficiency or dysfunction of C1 inhibitor protein. Treatment includes on-demand therapy for attacks and prophylactic medications to prevent episodes.
Clinical trials are advancing new treatments for hereditary angioedema. Currently, 8 studies are recruiting a combined 702 participants across the United States. Research is being conducted by 6 organizations including Astria Therapeutics, Inc., Pharvaris Netherlands B.V., Octapharma and 3 others.
2026 Hereditary Angioedema Research Landscape
As of March 2026, the hereditary angioedema clinical trial landscape includes 8 actively recruiting studies across 47 cities in the United States. These studies are collectively seeking 702 participants, with an average enrollment target of 88 per study.
Research is being led by 6 different organizations, including Astria Therapeutics, Inc., Pharvaris Netherlands B.V., Octapharma, KalVista Pharmaceuticals, Ltd., CSL Behring, and 1 others.
Geographically, hereditary angioedema trials are most concentrated in Santa Monica, California (6 trials); San Diego, California (4 trials); Walnut Creek, California (4 trials); St Louis, Missouri (4 trials); Birmingham, Alabama (3 trials) and 7 other cities.
Featured Hereditary Angioedema Studies
Highlighted recruiting studies for hereditary angioedema, selected by enrollment size and research scope.
A Study of Navenibart in Participants With Hereditary Angioedema
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in partici...
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks
Frequently Asked Questions About Hereditary Angioedema Clinical Trials
Are there hereditary angioedema clinical trials near me?
Yes, there are 8 hereditary angioedema clinical trials currently recruiting across 47+ cities in the United States, including Santa Monica, California; San Diego, California; Walnut Creek, California. Browse the studies above to find one at a location convenient for you.
How do I join a hereditary angioedema clinical trial?
To join a hereditary angioedema clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are hereditary angioedema clinical trials free?
Yes, participation in hereditary angioedema clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of hereditary angioedema treatments are being studied?
Current hereditary angioedema clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 6 research organizations.
Is it safe to participate in hereditary angioedema clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov